Business Context and Reporting Period
This Form 6-K filing by Immuron Limited (ASX: IMC) covers the month of October 2022, specifically dated October 13, 2022. The report serves to disclose a corporate announcement made to the Australian Securities Exchange regarding an investment activity.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a specific corporate event rather than a periodic financial statement.
Material Changes
The primary material event disclosed is an investment by Immuron Limited in Ateria Health, described in the announcement as a "leading gut health biotech." No other material changes to the company's financial position or operations are detailed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It does not explicitly list new risks or contingencies beyond the inherent nature of the disclosed investment. The filing includes a standard disclaimer stating it is not deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the terms and size of the investment in Ateria Health by reviewing the attached Exhibit 99.1.
- Confirm the strategic rationale for the investment in the gut health sector.
- Check subsequent filings for any financial impact of this investment on Immuron's balance sheet.